Keyphrases
Tuberous Sclerosis Complex
100%
Metastatic Renal Cell Carcinoma (mRCC)
82%
TSC1
25%
Rapalogs
24%
Neurodevelopmental Outcome
24%
Targeted Therapy
22%
Clinical Benefit
19%
Epilepsy
19%
Clinical Features
17%
Epilepsy Outcome
16%
Disease Transmission
16%
Disease Risk
16%
Ipilimumab
16%
Low-level Mosaicism
16%
Clinical Risk
16%
Renal Cell Carcinoma
15%
Metastatic RCC
14%
Autism Spectrum Disorder
13%
MTOR Pathway
13%
Epileptiform
13%
Sunitinib
12%
Systemic Therapy
12%
Breast Cancer Patients
12%
Pathway Genes
12%
Overall Survival
11%
Pathogenic Variants
11%
Confidence Interval
10%
Clinical Database
10%
Everolimus
10%
In Cancer
10%
Seizure
10%
Neurodevelopment
10%
Electroencephalography
10%
Adverse Events
9%
Electroencephalography Activity
9%
Prospective Cohort Study
9%
Middle East
9%
Young Age
9%
Metastatic Breast Cancer
9%
MTOR Inhibitor
9%
Survival Outcomes
8%
Clinical Seizure
8%
Non-aspirin Non-steroidal Anti-inflammatory Drugs
8%
Single nucleotide Polymorphism
8%
Transmission Genetics
8%
Excel
8%
Fetal Brain Magnetic Resonance Imaging
8%
Signet Ring
8%
Leptomeningeal Carcinomatosis
8%
Poor Risk
8%
Medicine and Dentistry
Kidney Metastasis
65%
Tuberous Sclerosis
49%
Neoplasm
23%
Magnetic Resonance Imaging
20%
Targeted Therapy
19%
Clear Cell Renal Cell Carcinoma
17%
Mammalian Target of Rapamycin
16%
Prevalence
16%
Ipilimumab
16%
Malignant Neoplasm
16%
Mosaicism
14%
Diseases
13%
Epileptic Seizure
12%
Systemic Therapy
12%
Metastatic Carcinoma
12%
Everolimus
10%
Clinical Feature
10%
Sunitinib
10%
Cancer Treatment
9%
Surgery
9%
Mammalian Target of Rapamycin Inhibitor
9%
Tyrosine-Kinase Inhibitor
8%
Metastatic Melanoma
8%
Tertiary Care
8%
Lenvatinib
8%
Glycon
8%
Prospective Cohort Study
8%
Horizontal Disease Transmission
8%
Programmed Death-Ligand 1
8%
Tumor Microcirculation
8%
Immune-Related Adverse Events
8%
Immunotherapy
8%
Electroencephalogram
8%
Medicine
8%
Colorectal Carcinoma
8%
Cancer Stem Cell
8%
PARP Inhibitor
8%
Nerve Cell Differentiation
8%
Tumor Cell
8%
Pharmacogenomics
8%
DNA Methylation
8%
Single Nucleotide Polymorphism
8%
Immune-Related Gene
8%
Cancer Pathobiology
8%
Sprouting Angiogenesis
8%
Microcirculation
8%
Cell-Free DNA
8%
DNA Determination
8%
Erythrocyte
8%
Adverse Event
7%